Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma
Sponsor
Celgene Corporation (Industry)
Overall Status
Completed
CT.gov ID
NCT00055562
Collaborator
(none)
274
31
23
8.8
0.4
Study Details
Study Description
Brief Summary
Subjects are randomized to one of two treatment arms. All subjects are screened for eligibility within 28 days prior to randomization. The study consists of a treatment phase and a follow-up phase. Subjects will be treated in repeating 4 week cycles.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2/Phase 3 |
Study Design
Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double
Primary Purpose:
Treatment
Official Title:
Multicenter, Randomized, Controlled, Double-Blind, Parallel-Group Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma Whose Disease Has Progressed on Treatment With DTIC, IL-2 or IFN Based Therapy
Study Start Date
:
Jan 1, 2003
Study Completion Date
:
Dec 1, 2004
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
-
Understand and voluntarily sign an informed consent form.
-
Able to adhere to the study visit schedule and other protocol requirements.
-
Metastatic malignant melanoma now stage IV, relapsed or refractory to standard metastatic therapy.
-
Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days of starting study drug.
-
Patients with active brain disease, or newly diagnosed brain metastases, within 4 weeks prior to the start of study treatment are excluded.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | University of Arizona Cancer Center | Tucson | Arizona | United States | 85724 |
2 | University of Southern California Norris Cancer Center | Los Angeles | California | United States | 90089 |
3 | UCLA | Los Angeles | California | United States | 90095-6956 |
4 | St. Francis Memorial Hospital | San Francisco | California | United States | 94109 |
5 | Outpatient Clinic | Santa Monica | California | United States | 90404 |
6 | University of Colorado | Aurora | Colorado | United States | 80010 |
7 | The Harold Lever Regional Cancer Center | Waterbury | Connecticut | United States | 06708 |
8 | Lakeland Regional Cancer Center | Lakeland | Florida | United States | 33804-1057 |
9 | Mount Sinai Comprehensive Cancer Center | Miami Beach | Florida | United States | 33140 |
10 | Lutheran General | Park Ridge | Illinois | United States | 60068-1270 |
11 | Carle Clinic | Urbana | Illinois | United States | 61801 |
12 | Massachusetts General Hospital | Boston | Massachusetts | United States | 02214-2698 |
13 | Beth Israel Deaconess Medical Ctr | Boston | Massachusetts | United States | 02215-5400 |
14 | Spectrum Health | Grand Rapids | Michigan | United States | 49503 |
15 | Ellis Fischel Cancer Center | Columbia | Missouri | United States | 65203 |
16 | Washington University School of Medicine | St. Louis | Missouri | United States | 63110 |
17 | Melanoma Center of St Louis | St. Louis | Missouri | United States | 63131 |
18 | Biomedical Research Alliance of New York | New York | New York | United States | 10016 |
19 | Memorial Sloan Kettering Cancer Center | New York | New York | United States | 10021 |
20 | The Linder Clinical Trial Center | Cincinnati | Ohio | United States | 45219 |
21 | Cleveland Clinic Foundation | Cleveland | Ohio | United States | 44195 |
22 | Penn State Hershey Medical Center | Hershey | Pennsylvania | United States | 17033-0850 |
23 | UPMC Cancer Pavillion | Pittsburgh | Pennsylvania | United States | 15232 |
24 | Sarah Cannon Cancer Center | Nashville | Tennessee | United States | 37203-1632 |
25 | MD Anderson Cancer Center | Houston | Texas | United States | 77030-4009 |
26 | Tom Baker Cancer Center | Calgary | Alberta | Canada | T2N 4N2 |
27 | Cross Cancer Institute | Edmonton | Alberta | Canada | T6G 1Z2 |
28 | Cancer Care Manitoba | Winnipeg | Manitoba | Canada | R3E 0V9 |
29 | Qell Health Sciences Center | Halifax | Nova Scotia | Canada | B3H 2y9 |
30 | Princess Margaret Hospital | Toronto | Ontario | Canada | M5G 2M9 |
31 | L'Hotel Dieu de Quebec | Quebec | Canada | PQ G1R 2J6 |
Sponsors and Collaborators
- Celgene Corporation
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00055562
Other Study ID Numbers:
- CDC-5013-MEL-001
- NCT00060281
First Posted:
Mar 6, 2003
Last Update Posted:
Jun 24, 2005
Last Verified:
May 1, 2004
Keywords provided by ,
,
Additional relevant MeSH terms: